Elanco Animal Health, Inc.

Elanco Animal Health, Inc.

Elanco Animal Health, Inc.

Overview
Date Founded

1954

Headquarters

2500 Innovation Way, Greenfield, IN, 46140, USA

Type of Company

Public

Employees (Worldwide)

5,760

Industries

Livestock & Animals
Hospitals & Patient Services
Agriculture & Mills

Company Description

Elanco Animal Health, Inc. engages in the innovation, development, manufacture and market products for companion and food animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded on May 3, 2018 and is headquartered in Greenfield, IN.

Contact Data
Trying to get in touch with decision makers at Elanco Animal Health, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President, Chief Executive Officer & Director

Executive Vice President & Chief Financial Officer

Chief Marketing Officer & Executive Vice President

Chief Sustainability Officer

Vice President & Chief Accounting Officer

Executive Vice President & President-International

Head-Global Media Relations

Vice President & Corporate Controller

Director-Dairy Business Unit

Executive Vice President, Innovation, Regulatory & Business Development

Board of Directors

Former Chief Executive Officer at Ball Corporation

Founder at Sachem Head Capital Management LP

Executive Vice President & Chief Financial Officer at Valeant Pharmaceuticals International Corp.

Limited Partner at Lead Edge Capital Management LLC

Co-Founder at WFD Ventures LLC

Former Executive Vice President & Chief Financial Officer at Ryder System, Inc.

Chairman of the Board, President & Chief Executive Officer at McCormick & Co., Inc.

Chief Executive Officer & Co-Founder at Mereo BioPharma Group Plc

President, Chief Executive Officer & Director at Elanco Animal Health, Inc.

Paths to Elanco Animal Health, Inc.
Potential Connections via
Relationship Science
You
Elanco Animal Health, Inc.
Owners & Shareholders
Details Hidden

JCM seeks to add value versus benchmarks by actively pursuing alpha generation through their own intensive fundamental research for their fundamental investment strategies. They look for companies possessing the firm’s key investment criteria through proprietary research that emphasizes contact with a company’s management team, competitors, suppliers and consumers, as well as in-depth and ongoing financial modeling. Holdings are generally selected one at a time with all other factors (industry, sector, country and cash allocations) being a residual of the investment process. JCM favors businesses that their research reveals have sustainable, above-average earnings growth potential and outstanding free cash flow generation, recurring revenue, profit margins and return on invested capital for their equity strategies. To build a mosaic of information in an effort to identify macro trends and inform allocations across fixed income sectors, the firm uses fundamental credit research.

Details Hidden

PRIMECAP Management aims to provide superior long-term investment results by utilizing fundamental research and bottom-up stock picking to construct portfolios. The firm looks for stocks that will outperform the market over a three to five-year horizon. PRIMECAP Management does not have a committee or small group that decides on whether or not to invest in an idea. Each portfolio manager makes an individual decision whether or not to invest in new ideas.

Details Hidden

Sachem Head Capital Management seeks to generate attractive risk-adjusted returns by employing a concentrated, value-oriented long/short investment strategy with the willingness to use activism. Their funds invest primarily in North American equities, but will also opportunistically invest overseas and in distressed credit situations that offer the potential for equity-like returns. Sachem Head Capital typically invests in securities that have market capitalizations in excess of $500 million and daily trading volume in excess of $3 million.

Recent Transactions
Details Hidden

Elanco Animal Health, Inc. issued USD Common Stock

Details Hidden

Elanco Animal Health, Inc. issued USD Common Stock

Details Hidden

Dechra Pharmaceuticals Plc purchases Elanco Animal Health, Inc. /Osurnia Bus from Elanco Animal Health, Inc.

Transaction Advisors
Legal Advisor

Advised onElanco Animal Health, Inc. issued USD Common Stock

Legal Advisor

Advised onElanco Animal Health, Inc. issued USD Common Stock

Legal Advisor

Advised onElanco Animal Health, Inc. issued USD Common Stock

Legal Advisor

Advised onElanco Animal Health, Inc. issued USD Common Stock

Legal Advisor

Advised onElanco Animal Health, Inc. issued USD Common Stock

Counsel

Advised onElanco Animal Health, Inc. issued USD Common Stock

Advisors & Consultants
Advisor

Former Vice President-Marketing at Marrone Bio Innovations, Inc.

Clients

Covetrus, Inc. engages in developing technologies and services for animal health industry. It also provides products, software, and services to help drive improved patient health, strong client relationships and successful financial outcomes for veterinary professionals. The firm geographically operates through the segments: North America, Europe and Asia Pacific (APAC) & Emerging Markets. The company was founded by Benjamin J. Shaw in 2014 and is headquartered in Portland, ME.

AmerisourceBergen Corp. engages provision of pharmaceutical products and business solutions that improve access to care. It operates through the Pharmaceutical Distribution Services and Other segments. The Pharmaceutical Distribution Services segment distributes a comprehensive offering of brand-name, specialty brand-name & generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies & equipment, outsourced compounded sterile preparations, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent & chain retail pharmacies, mail order pharmacies, medical clinics, long-term care & alternate site pharmacies, and other customers. The Other segment focuses on global commercialization services and animal health and includes ABCS, World Courier, and MWI. The company is headquartered in Chesterbrook, PA.

PetMed Express, Inc. engages in the provision of markets prescription and non-prescription pet medications, health products and supplies for dogs and cats. Its non-prescription medications include flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies. The prescription medications include heartworm preventatives, arthritis, thyroid, diabetes and pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The firm markets its products through national television, online and direct mail or print advertising campaigns. The company was founded in January 1996 and is headquartered in Delray Beach, FL.

Key Stats and Financials As of 2019
Market Capitalization
$13.7B
Total Enterprise Value
$13B
Earnings Per Share
$0.18
Revenue
$3.07B
Net Profit
$67.9M
Debt TEV
0.19x
TEVNet Income
191.47x
Enterprise Value EBITDAOperating
18.87x
Enterprise Value / Sales
4.23x
Total Equity
$5.55B
Total Debt
$2.44B
EBITDAMargin
22.29%
EBITDA
$684M
Three Year Compounded Annual Growth Rate Of Revenue
1.77%
Non-Profit Donations & Grants
Investments
Details Hidden

Boragen, Inc. engages in the design and developemnt of novel solutions targeting needs in crop protection, animal health and human health. It specializes in chemistry, research, and biotechnology. The company was founded by Stephen J. Benkovic, Gerald R. Fink, Lucy Shapiro, Paul R. Schimmel and C. Tony Liu in 2015 and is headquartered in Durham, NC.

Details Hidden

AgTech Accelerator Corp. focuses on discovering and developing agricultural technology companies. It offers finance to agricultural firms. The company was founded in 2003 and is headquartered in Durham, NC.

Details Hidden

Vindara, Inc. operates as an agriculture technology company, which engages in the provision of seeds for indoor farming. The company was founded by Roger Kemble and Jade Stinson and is headquartered in Durham, NC.

Suppliers
MDC Partners, Inc. Other Business & Consulting Services | New York, NY

MDC is a Business Transformation Organization that utilizes technology, marketing communications, data analytics, and strategic consulting solutions to drive meaningful returns on Marketing and Communications Investments for multinational clients in the United States, Canada, Europe, and the Caribbean. MDC’s durable competitive advantage is to Empower the Most Talented Entrepreneurial Thought Leaders to Drive Business Success to new levels of Achievement, for both our Clients and our Shareholders, reinforcing MDC's reputation as "The Place Where Great Talent Lives." MDC Partners' Class A shares are publicly traded on the NASDAQ under the symbol "MDCA" and on the Toronto Stock Exchange under the symbol "MDZ.A".

Aratana Therapeutics, Inc. Biotechnology | Kansas City, KS

Aratana Therapeutics, Inc. engages in the development and commercialization of pet therapeutics. Its portfolio includes NOCITA, ENTYCE, and GALLIPRANT. NOCITA (bupivacaine liposome injectable suspension) acts as a local post-operative analgesia for cranial cruciate ligament surgery in dogs, and as a peripheral nerve block to provide regional post-operative analgesia following onychectomy in cats. ENTYCE(capromorelin oral solution) is intended for appetite stimulation in dogs. GALLIPRANT (grapiprant tablets) is for the control of pain and inflammation associated with osteoarthritis in dogs. The company was founded by Linda Rhodes and Steven St. Peter on December 1, 2010 and is headquartered in Leawood, KS.

Heska Corp. Pharmaceuticals | Loveland, Colorado

Heska Corp. engages in the provision of veterinary and animal health diagnostic, and specialty products. It operates through the North America and International segments. The North America segment includes the United States, Canada, and Mexico. The International segment involves Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company was founded by Robert B. Grieve and Lynnor B. Stevenson in 1988 and is headquartered in Loveland, CO.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

DuPont de Nemours, Inc. Plastics & Synthetics - Wilmington, DE

DuPont de Nemours, Inc. operates as a holding company, which engages in the development of specialty materials, chemicals, and agricultural products. It operates through the following segments: Electronics & Imaging, Nutrition & Biosciences, Transportation & Industrial, Safety & Construction, and Non-Core. The Electronics & Imaging segment provides permanent and process chemistries for the fabrication of printed circuit boards to include laminates and substrates, electroless and electrolytic metallization solutions, as well as patterning solutions and materials and innovative metallization processes for metal finishing, decorative, and industrial applications. The Nutrition & Biosciences segment provides solutions for the global food and beverage, dietary supplements, pharma, home and personal care, energy and animal nutrition markets. The Transportation & Industrial segment engineering resins, adhesives, silicones, lubricants and parts to engineers and designers in the transportation, electronics, healthcare, industrial and consumer end-markets to enable systems solutions for demanding applications and environments. The Safety & Construction segment provides engineering products and integrated systems for a number of industries including, worker safety, water purification and separation, aerospace, energy, medical packaging and building materials. The Non-Core segment supplier of key materials for the manufacturing of photovoltaic cells and panels, including SOLAMET metallization pastes, TEDLAR backsheet materials, and FORTASUN silicone encapsulants and adhesives. The company was founded in 1897 and is headquartered in Wilmington, DE.

Zoetis, Inc. Pharmaceuticals

Zoetis is a global animal health company dedicated to supporting customers and their businesses in ever better ways. Building on more than 65 years of experience, we deliver quality medicines, vaccines and diagnostic products, complemented by genetic tests, biodevices and a range of services. We are working every day to better understand and address the real-world challenges faced by those who raise and care for animals in ways they find truly relevant.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Elanco Animal Health, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Elanco Animal Health, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Elanco Animal Health, Inc..